Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Specific class II HDAC inhibitors for beta-thalassemia and sickle cell anemia treatment

June 15, 2005

Long-term effects reported for febuxostat in hyperuricemia and gout

June 14, 2005

Fast track designation for Laszarin for heart failure in diabetes patients

June 14, 2005

FDA extends action date for SomatoKine NDA

June 14, 2005

New treatments for obesity and other metabolic disorders disclosed

June 13, 2005

AMG-641 shows promising preclinical results for hyperparathyroidism treatment

June 13, 2005

Asoprisnil recruits coactivators to target gene promoters

June 13, 2005

EP-1572 shows activity as growth hormone secretagogue in healthy volunteers

June 10, 2005

Byetta launched for type 2 diabetes

June 10, 2005

Altus looks to phase II studies of ALTU-238

June 10, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...